Akebia Therapeutics
Biotechnology ResearchMassachusetts, United States201-500 Employees
Akebia Therapeutics is a growing, mid-sized biopharmaceutical company based in Cambridge, Massachusetts, focused on the development and commercialization of therapies for people living with kidney disease. It operates within the biotechnology research sector and maintains an active pipeline of kidney-related therapeutics. The company’s work reflects a commitment to advancing treatments for renal conditions. In 2026, Akebia expanded its office presence to Waltham, Massachusetts, and was awarded a headquarters project in a life sciences building there, signaling regional growth. The company is advancing a kidney-disease pipeline that includes Phase 2 programs for praliciguat and AKB-097 and a Phase 1 study of AKB-9090. This positions Akebia as a development-focused participant in the kidney disease segment of the biopharmaceutical industry.